Formulary Exclusion vs Prior Authorization: 2026 Guide for Billing Teams

What's the Difference Between a Formulary Exclusion and a Prior Authorization Denial?

These two denial types look almost identical on a remittance, but they come from fundamentally different parts of a plan's benefit design — and the recovery path is completely different.

A prior authorization (PA) denial means the drug IS on the formulary, but the plan determined the patient did not meet the clinical criteria (step therapy, diagnosis, age, prior trials, etc.). The fix is a clinical appeal: send chart documentation that satisfies the criteria.

A formulary exclusion means the drug is NOT on the plan's covered drug list at all — usually because the PBM negotiated with a competitor manufacturer for a preferred rebate. There are no clinical criteria to meet because the plan never agreed to cover the drug in the first place. The fix is a Formulary Exception Request, which asks the plan to make a one-off exception based on medical necessity for THIS patient.

Field data from medical billing teams suggests roughly 85% of pharmacy benefit denials are actually formulary exclusions, not PA denials. Treating them the same way is why a lot of "appeals" go nowhere.

How to Identify Which One You're Dealing With (Different Denial Codes)

Formulary exclusions and PA denials use different rejection codes at the pharmacy point-of-sale. Knowing the codes lets your billing team route the case correctly within minutes instead of days.

• ✓ NCPDP reject 70 — "Product/Service Not Covered" — formulary exclusion (drug is off the formulary entirely)
• ✓ NCPDP reject 75 — "Prior Authorization Required" — PA denial (drug is on formulary but needs clinical approval)
• ✓ NCPDP reject 76 — "Plan Limitations Exceeded" — quantity limit, often paired with PA
• ✓ NCPDP reject MR — "Product Not on Formulary" — explicit formulary exclusion
• ✓ NCPDP reject 569 — "Provide Notice: Medicare Prescription Drug Coverage and Your Rights" — Part D point-of-sale rejection that triggers the patient's right to a coverage determination
• ✓ EOB code OA-96 (CARC) — "Non-covered charge(s)" — typically formulary exclusion when paired with RARC N130
• ✓ CARC 197 — "Precertification/authorization absent" — PA was needed and not obtained

Filing a Formulary Exception Request (vs a Standard PA Appeal)

A standard PA appeal argues "the patient meets your published criteria — here is the documentation." A Formulary Exception Request argues something different: "your formulary alternatives are medically inappropriate for this specific patient, and we are asking you to cover a non-formulary drug instead."

For Medicare Part D, the federal regulation governing this is 42 CFR § 423.578 — the formulary exception standard. The plan must grant the exception when the prescriber submits a supporting statement that the formulary alternatives "would not be as effective for the enrollee or would have adverse effects" (or both). That statutory language is the script: your supporting statement should mirror it.

For commercial plans (ERISA-governed self-funded groups and fully insured plans), the ACA requires that group health plans offer an exceptions process for non-formulary drugs (45 CFR § 156.122(c)). Most plans publish a "Non-Formulary Exception" or "Formulary Exception" form on their provider portal. The structure is similar to Part D but the deadlines and external review pathways are different.

CMS Model Coverage Determination Request Form (For Part D)

CMS publishes a standardized form — "Request for Medicare Prescription Drug Coverage Determination" (CMS-10146) — that every Part D plan must accept. Using the model form prevents the plan from rejecting your request on a technicality and starts the regulatory clock immediately.

• ✓ Section 1 — Enrollee information (name, Medicare ID, DOB, address)
• ✓ Section 2 — Prescriber information and signature
• ✓ Section 3 — Drug requested (name, strength, dosage form, quantity, days supply)
• ✓ Section 4 — Type of request: check "I need a drug that is not on the plan's list of covered drugs (formulary exception)"
• ✓ Section 5 — Expedited request box (check if standard timeline would jeopardize life, health, or function)
• ✓ Supporting statement — the prescriber's clinical justification, ideally addressing the § 423.578 standard explicitly

Part D Timelines (Memorize These)

Part D coverage determinations and appeals run on strict regulatory clocks. Missing a deadline almost always forfeits the appeal.

• ✓ Standard coverage determination — 72 hours from receipt of prescriber's supporting statement
• ✓ Expedited coverage determination — 24 hours
• ✓ Redetermination (Level 1 appeal) — 7 days standard, 72 hours expedited
• ✓ IRE Reconsideration (Level 2) — 7 days standard, 72 hours expedited
• ✓ ALJ hearing (Level 3) — case must exceed amount-in-controversy threshold ($190 in 2026)
• ✓ Medicare Appeals Council (Level 4) — no deadline for the Council's decision
• ✓ Federal District Court (Level 5) — case must exceed $1,900 amount in controversy (2026)

Off-Label Exclusions: When the Drug Is Approved But the Plan Won't Cover It for THAT Indication

A particularly tricky subcategory: the drug is on the formulary, but only for specific FDA-approved indications. Use the same drug for an off-label indication and the claim rejects as a formulary exclusion even though the drug itself is "covered."

This is increasingly common with GLP-1 receptor agonists. A plan may cover semaglutide (Wegovy) for chronic weight management with BMI ≥ 30, but exclude it for off-label use in MASH (metabolic dysfunction-associated steatohepatitis) or for obstructive sleep apnea — even after the FDA approved tirzepatide (Zepbound) for OSA in December 2024 and even when the patient has a documented OSA diagnosis.

For Part D, indication-based formulary exclusions can be challenged through a formulary exception when the prescriber demonstrates medical necessity. Citing AHFS DI, DrugDex, or the NCCN compendium for the specific off-label use is critical because Part D plans must cover drugs for "medically accepted indications" defined by 42 USC § 1396r-8(g)(1)(B)(i) — which incorporates these compendia by statute.

Step-by-Step: How to File a Successful Formulary Exception

Most formulary exception denials are caused by missing or weak documentation, not by the underlying clinical case. This is the workflow that consistently wins.

• ✓ Step 1 — Confirm it's a formulary exclusion (NCPDP 70, MR, or "non-formulary" language on the EOB), not a PA denial
• ✓ Step 2 — Pull the plan's formulary and identify every covered alternative in the same therapeutic class
• ✓ Step 3 — Document why each alternative is inappropriate: prior failure, contraindication, intolerance, or expected adverse outcome
• ✓ Step 4 — Write a supporting statement that mirrors the § 423.578 standard ("formulary alternatives would not be as effective" and/or "would have adverse effects")
• ✓ Step 5 — Attach chart evidence: prior therapy dates, doses, durations, discontinuation reasons, and labs/notes documenting outcomes
• ✓ Step 6 — Submit on the CMS Model Form (Part D) or the plan's Formulary Exception form (commercial). Mark expedited if clinically warranted and attest to urgency
• ✓ Step 7 — Calendar the response deadline (24 or 72 hours for Part D). If no response by deadline, the request is "deemed approved" under federal regulation and you can demand the plan honor it
• ✓ Step 8 — If denied, file Level 1 redetermination within 60 days (Part D) or per the plan's commercial timeline

Real Example: Wegovy/Zepbound for Sleep Apnea — The Formulary Exclusion Battle

In December 2024, the FDA approved tirzepatide (Zepbound) for moderate-to-severe obstructive sleep apnea in adults with obesity — making it the first drug ever approved for OSA. Despite the on-label indication, many commercial plans and most Part D plans continue to exclude GLP-1s from their formularies for any weight-related indication, including the new OSA indication.

The recovery pattern that works: (1) document the patient's OSA diagnosis with sleep study AHI ≥ 15, (2) document obesity (BMI ≥ 30), (3) document failure or intolerance of CPAP/BiPAP including specific dates and the reason for discontinuation, (4) submit a formulary exception citing the FDA on-label indication and the AASM/ACP guideline support for pharmacotherapy in CPAP-intolerant patients, and (5) explicitly state that no formulary alternative exists with the same indication (because Zepbound is the only FDA-approved drug for OSA).

For Wegovy used off-label for MASH, the supporting statement should cite the ESSENCE trial (NEJM 2025) demonstrating MASH resolution with semaglutide and the AASLD 2024 practice guidance on pharmacotherapy for MASH with fibrosis. Off-label MASH exceptions are denied more often than on-label OSA exceptions, but external review reverses many of them when the trial evidence is cited specifically.

When to Escalate to External Review (And When to Give Up)

External review is independent — it removes the decision from the plan and gives it to a contracted Independent Review Organization (IRO). For drug denials, external review reverses the plan roughly 40-50% of the time when clinical evidence is strong, and higher for Part D Level 4 (Medicare Appeals Council) reviews of expensive specialty drugs.

• ✓ Commercial ERISA plans — federal external review under 29 CFR § 2590.715-2719 within 4 months of final internal denial; binding on the plan
• ✓ Commercial fully insured plans — state external review process (NAIC model law adopted by all 50 states), typically 4 months from final internal denial
• ✓ State-specific external review — most states use a state-contracted IRO; California (DMHC IMR), New York (DFS External Appeal), and Texas (TDI IRO) have particularly active processes with public outcome data
• ✓ Medicare Part D — automatic forward to Independent Review Entity (IRE) after Level 1; further escalation to ALJ requires amount in controversy ≥ $190
• ✓ Medicaid — state fair hearing through the Medicaid agency; deadlines vary but typically 90-120 days from notice of action
• ✓ When to stop — if the FDA label doesn't support the indication, no compendium (AHFS DI, DrugDex, NCCN, Clinical Pharmacology) lists the use, and no peer-reviewed RCT supports it, external review will likely uphold the denial. The patient's clinician and the practice need to discuss alternatives.

How RxCheckUp Handles Formulary Exclusions Differently

Most appeal tools treat every denial as a PA appeal. RxCheckUp identifies whether a denial is a formulary exclusion or a PA denial from the rejection code or denial letter, then routes to the correct workflow: a Formulary Exception Request with § 423.578-mirroring supporting statement language for Part D, or the plan-specific Non-Formulary Exception form for commercial. The platform pulls the patient's prior therapy history, identifies why each formulary alternative is inappropriate, and drafts the supporting statement so the prescriber only has to review and sign.